- Home
- NHS vs VNDA Comparison
NHS vs VNDA Comparison
Compare NHS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- VNDA
- Stock Information
- Founded
- NHS 2003
- VNDA 2002
- Country
- NHS United States
- VNDA United States
- Employees
- NHS N/A
- VNDA N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- VNDA Health Care
- Exchange
- NHS Nasdaq
- VNDA Nasdaq
- Market Cap
- NHS 226.7M
- VNDA 260.0M
- IPO Year
- NHS N/A
- VNDA 2006
- Fundamental
- Price
- NHS $7.15
- VNDA $4.97
- Analyst Decision
- NHS
- VNDA Strong Buy
- Analyst Count
- NHS 0
- VNDA 3
- Target Price
- NHS N/A
- VNDA $14.00
- AVG Volume (30 Days)
- NHS 111.8K
- VNDA 1.0M
- Earning Date
- NHS 01-01-0001
- VNDA 10-29-2025
- Dividend Yield
- NHS 13.44%
- VNDA N/A
- EPS Growth
- NHS N/A
- VNDA N/A
- EPS
- NHS N/A
- VNDA N/A
- Revenue
- NHS N/A
- VNDA $212,074,000.00
- Revenue This Year
- NHS N/A
- VNDA $14.32
- Revenue Next Year
- NHS N/A
- VNDA $37.05
- P/E Ratio
- NHS N/A
- VNDA N/A
- Revenue Growth
- NHS N/A
- VNDA 11.12
- 52 Week Low
- NHS $6.95
- VNDA $3.81
- 52 Week High
- NHS $9.17
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- NHS 38.70
- VNDA 54.57
- Support Level
- NHS $7.04
- VNDA $4.72
- Resistance Level
- NHS $7.27
- VNDA $5.46
- Average True Range (ATR)
- NHS 0.09
- VNDA 0.23
- MACD
- NHS -0.03
- VNDA 0.07
- Stochastic Oscillator
- NHS 25.88
- VNDA 61.34
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.